Compare OSBC & OCUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OSBC | OCUL |
|---|---|---|
| Founded | 1981 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2014 | 2014 |
| Metric | OSBC | OCUL |
|---|---|---|
| Price | $24.32 | $6.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | ★ $28.00 | $25.45 |
| AVG Volume (30 Days) | 593.1K | ★ 3.1M |
| Earning Date | 10-21-2026 | 11-10-2026 |
| Dividend Yield | ★ 1.30% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.02 | N/A |
| Revenue | N/A | ★ $1,990,000.00 |
| Revenue This Year | $13.70 | $1.70 |
| Revenue Next Year | $1.71 | $93.13 |
| P/E Ratio | $24.04 | ★ N/A |
| Revenue Growth | N/A | ★ 3.48 |
| 52 Week Low | $17.61 | $6.00 |
| 52 Week High | $26.06 | $16.44 |
| Indicator | OSBC | OCUL |
|---|---|---|
| Relative Strength Index (RSI) | 41.79 | 42.24 |
| Support Level | $24.01 | $6.79 |
| Resistance Level | $25.77 | $7.75 |
| Average True Range (ATR) | 0.56 | 0.43 |
| MACD | -0.03 | 0.15 |
| Stochastic Oscillator | 34.81 | 60.25 |
Old Second Bancorp Inc is a bank holding company. It provides consumer and commercial banking products such as demand, money market, savings, time deposit, and individual retirement as well as commercial, industrial, consumer, and real estate lending, including installment loans, student loans, agricultural loans, lines of credit and overdraft checking, safe deposit operations, trust services, wealth management services, and additional services tailored to the needs of individual customers, corporates, small-medium enterprises. The company has one operating segment, which is community banking. The company's revenue consists of interest, commission, payments, and other income.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.